vianib 100 mg kapsułki twarde
vianex s.a. - imatinibi mesilas - kapsułki twarde - 100 mg
vianib 400 mg kapsułki twarde
vianex s.a. - imatinibi mesilas - kapsułki twarde - 400 mg
mekinist
novartis europharm limited - trametynib - czerniak - Środki przeciwnowotworowe - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 i 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. niedrobnokomórkowego raka płuca (nsclc)trametinib w połączeniu z dabrafenib jest wskazany do leczenia dorosłych pacjentów z postępowym małym komórka nowotworem płuc z brugh mutacja v600 daleko .
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. efekt imatinib na wynik przeszczepienia szpiku kostnego nie jest określona. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. doświadczenie z imatinibom u pacjentów z mds/jest msy, związanych z pdgfr genów permutacji-bardzo ograniczony. brak kontrolowanych badań wykazują kliniczną korzyść lub zwiększone tempo dla tych chorób.
codipar 250 250 mg czopki
angelini pharma polska sp. z o.o. - paracetamolum - czopki - 250 mg
codipar 500 500 mg czopki
angelini pharma polska sp. z o.o. - paracetamolum - czopki - 500 mg
codipar 500 mg tabletki
angelini pharma polska sp. z o.o. - paracetamolum - tabletki - 500 mg
panadol femina (800 mg + 10 mg)/2,7 g czopki
glaxosmithkline consumer healthcare sp. z o.o. - paracetamolum + hyoscini butylbromidum - czopki - (800 mg + 10 mg)/2,7 g
panadol femina 500 mg + 10 mg tabletki powlekane
haleon poland sp. z o.o. - paracetamolum + hyoscini butylbromidum - tabletki powlekane - 500 mg + 10 mg
thromboreductin 0,5 mg kapsułki twarde
aop orphan pharmaceuticals gmbh - anagrelidum - kapsułki twarde - 0,5 mg